JFrog Partners with NVIDIA to Accelerate Agentic AI, Integrating the JFrog Platform with NVIDIA Enterprise AI Factory
SUNNYVALE, Calif.--(BUSINESS WIRE)-- COMPUTEX 2025 – JFrog Ltd (Nasdaq: FROG), the Liquid Software company and creators of the award-winning JFrog Software Supply Chain Platform, today announced the integration of its foundational DevSecOps tools with the NVIDIA Enterprise AI Factory validated design. JFrog will serve as the cornerstone software artifact repository and secure model registry for the landmark agentic AI architecture.
Big news! @JFrog is proud to serve as a cornerstone in @nvidia #Enterprise #AI Factory to accelerate the next generation of #agenticAI innovation. Read more: https://bit.ly/432sW1a #SoftwareSupplyChain #DevOps #DevSecOps #cybersecurity #developer #COMPUTE
Share
Following a successful NVIDIA NIM integration with the JFrog Platform, this new collaboration delivers a full-spectrum MLOps solution, designed to ensure scalable, secure and seamless deployment of AI-powered applications using the NVIDIA Blackwell platform.
"The future of AI depends not only on innovation - but on trust, control, and seamless execution," said Shlomi Ben Haim, CEO and co-founder of JFrog. "To deliver AI at scale, enterprises need to adopt the same concepts applied to software: developer-friendly workflows, strong security, robust governance, and full lifecycle management. ML models are binaries, and they must be managed as first-class software artifacts. That's why we're excited to partner with NVIDIA to bring JFrog's Software Supply Chain Platform as the single source of truth for all software and AI assets to the NVIDIA Enterprise AI Factory so organizations can build and scale trusted AI solutions with confidence."
Delivering Critical Infrastructure to Enable Future AI Innovation
The JFrog Platform provides customers with a 'single source of truth' for software components within NVIDIA Enterprise AI Factory, which contains an integrated and validated suite of software technology solutions enterprises can use to develop, deploy, and manage agentic AI, physical AI, and HPC workloads on-premises. This validated design aims to allow organizations to have full control of their data and operate advanced AI agents in a secure environment. Key capabilities include:
Secure & Governed Software Component Visibility: Enables all ML models, engines, and software artifacts to be scanned for security issues, versioned, governed, and traceable across the entire software development lifecycle.
End-to-End Software Artifact & ML Model Management: Enables the seamless pulling, uploading, and hosting of AI models and datasets, AI containers, Docker containers, and dependencies optimized for the NVIDIA Enterprise AI Factory validated design.
Rapid, Trusted AI/ML Application Provisioning in Runtime: Simplifies configuration of AI environments by eliminating the need for runtime environments to pull components from outside of the organization, thanks to the universality, proven scalability and robustness of JFrog Artifactory.
Future-proofed for Evolving GenAI Applications: Quickly and easily manages ML model versioning and upgrades to new and approved model generations.
'Enterprises building AI factories need to manage the complexity of AI adoption while ensuring performance, governance and trust,' said Justin Boitano, Vice President, Enterprise AI Software Products, NVIDIA. 'JFrog's unified software supply chain platform, paired with the NVIDIA Enterprise AI Factory validated design, enables rapid, responsible AI innovation at scale.'
The integration is designed to enable the JFrog Platform to run natively on NVIDIA Blackwell systems to help reduce latency and process tasks with unparalleled performance, efficiency, and scale. It supports a wide range of AI-enabled enterprise applications, agentic and physical AI workflows, autonomous decision-making, and real-time data analysis across various industries, including financial services, healthcare, telecommunications, retail, media, and manufacturing. Additionally, the system leverages NVIDIA's engineering know-how and partner ecosystem to help enterprises accelerate time-to-value and mitigate the risks of AI deployment.
Those interested in learning more about JFrog and NVIDIA integrations or going hands-on with the NVIDIA NIM trial should visit https://jfrog.com/jfrog-and-nvidia/.
Like this Story? Share this on X: Big news! @JFrog is proud to serve as a cornerstone in @nvidia #Enterprise #AI Factory to accelerate the next generation of #agenticAI innovation. Read more: https://bit.ly/432sW1a #SoftwareSupplyChain #DevOps #DevSecOps #cybersecurity #developer #COMPUTEX
About JFrog
JFrog Ltd. (Nasdaq: FROG) is on a mission to power the world with liquid software. We are replacing endless software updates with a single system of record that seamlessly delivers secure applications from developer to device. The JFrog Software Supply Chain Platform helps organizations build, manage, and distribute software quickly and securely, making applications available, traceable, and tamper-proof. Its integrated security features also help identify, protect, and remediate against threats and vulnerabilities. The Platform also brings ML models in line with all other software development processes, providing a single source of truth for all software components across Engineering, MLOps, DevOps, and DevSecOps teams so they can build and release AI applications faster, with minimal risk and less cost. JFrog's hybrid, universal, multi-cloud platform is available as both self-hosted and SaaS services across major cloud service providers. Millions of users and 7K+ customers worldwide, including a majority of the Fortune 100, depend on JFrog solutions to securely embrace digital transformation. Once you leap forward, you won't go back! Learn more at jfrog.com and follow us on X: @jfrog.
Cautionary Note About Forward-Looking Statements
This press release contains 'forward-looking' statements, as that term is defined under the U.S. federal securities laws, including, but not limited to, statements regarding JFrog's artifact repository and secure model registry's integration with NVIDIA's agentic AI architecture delivering a full-spectrum MLOps solution.
These forward-looking statements are based on our current assumptions, expectations, and beliefs and are subject to substantial risks, uncertainties, assumptions and changes in circumstances that may cause JFrog's actual results, performance or achievements to differ materially from those expressed or implied in any forward-looking statement. There are a significant number of factors that could cause actual results, performance or achievements to differ materially from statements made in this press release, including but not limited to risks detailed in our filings with the Securities and Exchange Commission, including in our annual report on Form 10-K for the year ended December 31, 2024, our quarterly reports on Form 10-Q, and other filings and reports that we may file from time to time with the Securities and Exchange Commission. Forward-looking statements represent our beliefs and assumptions only as of the date of this press release. We disclaim any obligation to update forward-looking statements except as required by law.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
30 minutes ago
- Associated Press
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Iovance To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Iovance between August 8, 2024 and May 8, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - June 8, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Iovance Biotherapeutics, Inc. ('Iovance' or the 'Company') (NASDAQ: IOVA) and reminds investors of the July 14, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. [ This image cannot be displayed. Please visit the source: ] Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose the true state of Iovance's growth potential; notably, that it was not equipped to generate and drive demand or was otherwise ill equipped to capitalize upon the purported existing demand for its treatments through its network of approved treatment centers. On July 25, 2024, Iovance announced its financial results for the second quarter of fiscal 2024 and reduced its revenue guidance for the full fiscal year 2024. The Company attributed its results and lowered guidance on 1) 'the iCTC completed annual scheduled maintenance in December' and 'capacity was reduced by more than half for about 1 month,' 2) "[l]ower Proleukin sales' than the company expected, and 3) 'the variable pace at which ATCs began treatment patients.' Investors and analysts reacted immediately to Iovance's revelation. The price of Iovance's common stock declined dramatically. From a closing market price of $3.17 per share on May 8, 2025, Iovance's stock price fell to $1.75 per share on May 9, 2025, a decline of about 44.795% in the span of just a single day. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding Iovance's conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the Iovance class action, go to or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( ). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner. To view the source version of this press release, please visit
Yahoo
an hour ago
- Yahoo
Microsoft Tops $3.5 Trillion Market Cap, Beats Nvidia
Microsoft (NASDAQ:MSFT) hit a new high as its market capitalization topped $3.5 trillion, edging out Nvidia (NASDAQ:NVDA) and solidifying its lead among the Magnificent Seven. Warning! GuruFocus has detected 5 Warning Sign with MSFT. Shares of Microsoft climbed to a record $467.68 on Thursday, up 0.8%, before adding another 0.6% on Friday to push its market cap past $3.5 trillion. Nvidia wasnt far behind, trading up 1.3% on Friday with a market cap of $3.47 trillion, while Apple (NASDAQ:AAPL) also breached the $3 trillion mark with a 1% gain to reach $3.02 trillion. Microsofts stock has outpaced the broader Nasdaq (IND), rising 11% year-to-date compared to the indexs modest sub-1% gain. The software giant has been powered by robust growth in its cloud unit, Azure, where revenue jumped 28% year-over-year in Q3 FY25, and by its deepening partnership with OpenAI, which has driven strong demand for AI-powered services. Bernstein Societe Generale Group raised its price target on Microsoft to $540 from $520, citing significant upside potential as Azure continues to scale and AI integration expands across enterprise offerings. Bernstein analysts retained their Outperform rating, noting that Microsofts diversified revenue streamsfrom Office 365 subscriptions to LinkedIn and gamingprovide a hedge against macro uncertainties. Nvidias gains have been fueled by surging demand for its H100 and H200 GPUs, which dominate the AI data-center market, helping it close the gap with Microsoft. Apples performance, meanwhile, reflects resilient iPhone sales and growing services revenue, which has climbed 17% year-over-year to $21 billion in Q2 FY25. Why It Matters: Microsofts $3.5 trillion valuation underscores the escalating AI and cloud war between the tech titans, where gains in enterprise adoption and AI partnerships can translate directly into market-cap milestones. The battle for supremacy now hinges on execution in generative AI, data-center infrastructure and enterprise software integrations. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
1 Stock Down 34% This Year to Buy and Hold
Investors are withdrawing their money from stocks like Viking Therapeutics due to the current uncertainty. However, the biotech has a duo of mid-stage candidates that look incredibly promising. Though it carries above-average risk, Viking has significant upside potential. 10 stocks we like better than Viking Therapeutics › Shares of Viking Therapeutics (NASDAQ: VKTX), a mid-cap biotech, are down by 34% this year. This poor performance may suggest that recent company-specific developments have rendered the stock less attractive or that it is being affected by broader market issues. The latter is true, at least to some extent, but Viking Therapeutics' thesis has not changed significantly this year. The drugmaker remains attractive compared to most of its similarly sized peers. Here is why. Viking Therapeutics is a clinical-stage biotech. That means the company has no product on the market, generates no revenue, and is consistently unprofitable. Investors aren't too keen on buying shares of companies that fit this profile when broader equities are experiencing significant volatility due to potential macroeconomic issues. In fairness, that makes sense. Clinical-stage biotechs carry above-average risk. Their products may never see the light of day outside the clinic, and even when they do, many do not generate substantial revenue. However, Viking Therapeutics is a bit different. The company is developing medicines across several areas with high unmet needs. First, there is the drugmaker's work in the weight management space. The anti-obesity drug market has experienced significant growth in recent years. Yet, analysts continue to predict that the best is yet to come. Viking Therapeutics' leading candidate in this area, VK2735, is a dual GLP-1/GIP agonist. The only approved medicine of this kind on the market is Eli Lilly's Zepbound, an undisputed leader. Being in the same class as Zepbound doesn't guarantee VK2735's success, but it's still worth pointing out that a similar mechanism of action that led to Zepbound's breakthrough and efficacy could also prove successful for Viking Therapeutics' crown jewel. And more importantly, the investigational medicine has produced better results than almost any other mid-stage candidate in weight management, outside of those being developed by Eli Lilly and Novo Nordisk. That's impressive for a mid-cap biotech, considering significantly larger drugmakers with far more resources are trying to dominate this market. Viking Therapeutics' other mid-stage program, VK2809, performed well in patients with metabolic dysfunction-associated steatohepatitis (MASH), a disease with obesity as one of the main risk factors and whose prevalence is on the rise. However, the U.S. Food and Drug Administration approved just the first MASH medicine last year, although that will likely change soon. The point, though, is that VK2809 could join a relatively young market in a few years and generate massive sales down the road. These two candidates set Viking Therapeutics apart from other clinical-stage biotech companies. It's also worth noting that Viking Therapeutics recently signed a multiyear manufacturing agreement with privately held CordenPharma for VK2735. Per the terms of the deal, CordenPharma will manufacture more than a billion oral formulations of the medicine annually, as well as over 100 million autoinjectors and another 100 million syringes per year. Viking Therapeutics will make payments to CordenPharma, totaling $150 million through 2028. This deal highlights that Viking Therapeutics is already planning some post-commercial activity for its leading candidate. That's a great sign for investors. Viking Therapeutics is developing other candidates, including another weight management product that is still in preclinical studies. Following a similar blueprint, this product is a dual agonist that mimics the action of not just one but two gut hormones: amylin, which helps regulate blood sugar, and calcitonin, which regulates calcium levels. There is slow progress on that front, but Viking Therapeutics' commitment to innovation is impressive for such a small biotech. Now, Viking Therapeutics' most advanced programs could fail in phase 3 studies. If that happens, especially with VK2735, the stock price is likely to plummet. That's a significant risk to consider. That's why the stock is probably not suitable for risk-averse investors. However, those who are comfortable with volatility should strongly consider initiating a small position in the stock. If the business goes under, which isn't that rare for smaller biotech companies, your losses will be relatively small so long as the company makes a tiny portion of your overall portfolio. But there is significant upside potential that those who invest in Viking Therapeutics today could enjoy over the long run. Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Prosper Junior Bakiny has positions in Eli Lilly, Novo Nordisk, and Viking Therapeutics. The Motley Fool recommends Novo Nordisk and Viking Therapeutics. The Motley Fool has a disclosure policy. 1 Stock Down 34% This Year to Buy and Hold was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
